[1]贾宇衡,杨 毅,洪立信,等.基于离散选择实验的胃癌患者治疗偏好研究[J].卫生经济研究,2025,42(04):28-32.
　JIA Yuheng,YANG Yi,HONG Lixin,et al.Study on Treatment Preference of Gastric Cancer Patients based on Discrete Choice Experiments[J].Journal Press of Health Economics Research,2025,42(04):28-32.
点击复制

基于离散选择实验的胃癌患者治疗偏好研究
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
42
期数:
2025年04期
页码:
28-32
栏目:
卫生服务利用
出版日期:
2025-04-02

文章信息/Info

Title:
Study on Treatment Preference of Gastric Cancer Patients based on Discrete Choice Experiments
作者:
贾宇衡1; 杨 毅2; 3; 洪立信4; 张 芃2; 5; 田 侃6; 王志刚7
1.南京中医药大学卫生经济管理学院，江苏 南京 210023
2.复旦大学公共卫生学院，上海 200032
3.国家卫生健康委员会卫生技术评估重点实验室（复旦大学）， 上海 200032
4.南京中医药大学药学院，江苏 南京 210023
5.上海应用技术大学人文学院，上海 201418
6.南京中医药大学养老服务与管理学院，江苏 南京 210023
7.江苏省肿瘤医院，江苏 南京 210009
Author(s):
JIA Yuheng;  YANG Yi;  HONG Lixin;  ZHANG Peng;  TIAN Kan;  WANG Zhigang
School of Health Economics and Management, Nanjing University of Chinese Medicine, Nanjing Jiangsu 210023, China
关键词:
离散选择实验; 胃癌患者; 治疗偏好
Keywords:
discrete choice experiment;  gastric cancer patients;  treatment preference
分类号:
R19
文献标志码:
A
摘要:
目的：研究胃癌患者治疗偏好的属性及水平，为胃癌患者治疗决策提供参考依据。方法：通过文献回顾，初步拟定胃癌患者治疗偏好的属性及水平；经过专家咨询及关键知情人访谈，确定属性及水平。结果：最终保留6个胃癌治疗偏好属性，分别为无进展（病）生存期、生命质量、给药频率、肿瘤相关症状、严重治疗副作用（＞3级）发生率、每月自付费用。结论：预实验显示，开发得到的胃癌患者治疗偏好的离散选择实验属性及相应水平符合实际且易于理解，可以为医患共同决策提供询证依据。
Abstract:
Objective To study the attributes and levels of treatment preferences of gastric cancer patients, and to provide a reference basis for treatment decision-making of gastric cancer patients. Methods The attributes and levels of treatment preferences of gastric cancer patients were initially formulated through literature review. The attributes and levels were determined after expert consultation and key informant interviews. Results 6 most concerned attributes of treatment preferences of gastric cancer patients were finally retained, which were progression-free survival, quality of life, frequency of drug administration, tumor-related symptoms, incidence of serious treatment side effect(>grade 3), and monthly out-of-pocket costs. Conclusion The pre-experiment showed that the developed discrete choice experiment attributes and corresponding levels of treatment preferences of gastric cancer patients were realistic and easy to understand, which could provide an evidence-based basis for joint decision-making between doctors and patients.

参考文献/References:

[1] F.Bray,M.Laversanne,H.Sung,et al.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].A Cancer J Clin,2024,74(03):229-263.
[2] W.L.Guan,Y.He,R.H.Xu.Gastric cancer treatment: recent progress and future perspectives[J].J Hematol Oncol,2023,16(01):57.
[3] Y.Zhang,H.Naci,A.K.Wagner, et al.Overall aurvival benefits of cancer drugs approved in China from 2005 to 2020[J].JAMA Netw Open,2022,5(08):e2225973.
[4] Bachelard C.Moreau,E.Coquan,P.du Rusquec,et al.Risks and benefits of anticancer drugs in advanced cancer patients:a systematic review and meta-analysis[J].E Clinical Medicine,2021(40):101130.
[5] 孙浩，刘尧，王家林，等.癌症患者参与医患共同决策行为意愿动力机制研究——基于计划行为理论模型和结构方程模型[J].中华肿瘤防治杂志，2023，30（20）：1236-1241.
[6] 李冬昀，陈英伟，赵德利，等.我国医患共同决策问题及优化路径[J].中国医院管理，2023，43（04）：82-85.
[7] 王秋臣，张秀英，薛辉，等.开发离散选择实验属性和水平的研究进展[J].现代预防医学，2020，47（12）：2199-2201，2210.
[8] A.B.Hauber,J.M.Gonzalez,C.G.Groothuis-Oudshoorn,et al.Statistical methods for the analysis of discrete choice experiments:a report of the ISPOR Conjoint analysis good research practices task force[J].Value Health,2016,19(04):300-315.
[9] E.Lancsar,J.Louviere.Conducting discrete choice experiments to inform healthcare decision making:a user's guide[J].Pharmacoeconomics,2008,26(08):661-677.
[10] D.R.Bien,M.Danner,V.Vennedey,et al.Patients' preferences for outcome,process and cost attributes in cancer treatment:a systematic review of discrete choice experiments[J].Patient,2017,10(05):553-565.
[11] H.Q.Li,H.Xue,H.Yuan,et al.Preferences of first-degree relatives of gastric cancer patients for gastric cancer screening: a discrete choice experiment[J].BMC Cancer,2021,21(01):959.
[12] Q.Wang,Y.Chen,Y.Peng,et al.Preferences of oral nutritional supplement therapy among postoperative patients with gastric cancer: Attributes development for a discrete choice experiment[J].PLoS One,2022,17(09):e0275209.
[13] H.Q.Li,H.Yuan,G.Y.Wan,et al.Preferences of gastric cancer survivors for follow-up care-a multicenter discrete choice experiment study[J].Support Care Cancer,2022,30(02):1221-1229.
[14] X.Peng,L.Hui-Qin,H.Xia.Whether preferences of gastric cancer patients after surgery for follow-up change over time?Analysis based on discrete choice experiment[J].Support Care Cancer,2023,31(04):234.
[15] 吕玉玉，李顺平，路立勇，等.基于离散选择实验的试管婴儿治疗偏好属性及水平开发研究[J].医学与社会，2024，37（07）：86-93.
[16] Z.Feng,J.Meng,Y.Sun,et al.Assessment of patients' preferences for new anticancer drugs in China:a best-worst discrete choice experiment on three common cancer types[J].BMJ Open,2023,13(06):e072469.
[17] C.Mansfield,W.Botha,G.T.Vondeling,et al.Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer:a discrete-choice experiment study[J].Breast Cancer,2023,30(01):23-35.
[18] E.Stamuli,S.Corry,D.Ross,et al.Patient preferences for breast cancer treatments: a discrete choice experiment in France, Ireland, Poland and Spain[J].Future Oncol,2022,18(09):1115-1132.
[19] S.Janse,E.Janssen,T.Huwig,et al.Line of therapy and patient preferences regarding lung cancer treatment:a discrete-choice experiment[J].Curr Med Res Opin,2021,37(04):643-653.
[20] X.Y.Wong,AQJ Lim,Q.Shen, et al.Patient preferences and predicted relative uptake for targeted therapies in metastatic colorectal cancer:a discrete choice experiment[J].Curr Med Res Opin,2020,36(10):1677-1686.
[21] S.J.Fifer,K.A.Ho,S.Lybrand,et al.Alignment of preferences in the treatment of multiple myeloma-a discrete choice experiment of patient,carer,physician,and nurse preferences[J].BMC Cancer,2020,20(01):546.
[22] 孙辉，陈英耀，任绍聪，等.非小细胞肺癌患者疾病治疗偏好与意愿支付研究[J].卫生经济研究，2018，34（09）：6-9.
[23] K.Schmidt,K.Damm,A.Vogel,et al.Therapy preferences of patients with lung and colon cancer:a discrete choice experiment[J].Patient Prefer Adherence,2017(11):1647-1656.
[24] A.C.Muhlbacher,S.Bethge.Patients' preferences:a discrete-choice experiment for treatment of non-small-cell lung cancer[J].Eur J Health Econ,2015,16(06):657-670.
[25] Y.K.Kang,K.Chin,H.C.Chung,et al.S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer(SOLAR):a randomised, open-label, phase 3 trial[J].Lancet Oncol,2020,21(08):1045-1056.
[26] G.Rosati,C.A.Cella,L.Cavanna,et al.A randomized phase III study of fractionated docetaxel,oxaliplatin,capecitabine(low-tox) vs epi-rubicin,oxaliplatin and capecitabine(eox) in patients with locally advanced unresectable or metastatic gastric cancer:the lega trial[J].Gastric Cancer,2022,25(04):783-793.
[27] A.Bausys,T.Umarik,O.Dobrzhanskyi,et al.Neoadjuvant chemo-therapy followed by gastrectomy for cytology-positive gastric cancer without any other non-curative factors in a western setting:an international eastern european cohort study[J].Cancers (Basel),2023,15(24):5794.
[28] C.K.Lee,H.S.Kim,M.Jung,et al.Open-label, multicenter,randomized,biomarker-integrated umbrella trial for second-line treatment of advanced gastric cancer:k-umbrella gastric cancer study[J].J Clin Oncol,2024,42(03):348-357.
[29] S.H.Park,D.H.Lim,T.S.Sohn, et al.A randomized phase III trial comparing adjuvant single-agent S1,S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial[J].Ann Oncol,2021,32(03):368-374.
[30] L.Su,S.Zhao,Y.Yin,et al.POF(paclitaxel/oxaliplatin/5-fluorouracil/leucovorin)vs.SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial,FNF-014 trial[J].Front Med (Lausanne),2022(09):861777.
[31] H.Hasegawa,K.Shitara,S.Takiguchi, et al.A multicenter,open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer[J].Gastric Cancer,2022,25(03):619-628.
[32] A.L.Versteeg,A.Sahgal,N.Kawahara,et al.Patient satisfaction with treatment outcomes after surgery and/or radiotherapy for spinal metastases[J].Cancer,2019,125(23):4269-4277.
[33] J.F.Bridges,M.la Cruz,M.Pavilack,et al.Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer[J].Future Oncol,2019,15(34):3895-3907.
[34] 孙康宁，张秀杰，王春辉，等.山东省中晚期结直肠癌患者生命质量现状及影响因素分析[J].中华肿瘤防治杂志，2023，30（15）：897-903.
[35] L.Fu,X.Feng,Y.Jin,et al.Symptom clusters and quality of life in gastric cancer patients receiving chemotherapy[J].J Pain Symptom Manage,2022,63(02):230-243.
[36] Y.Lin,S.L.Docherty,L.S.Porter,et al.Symptom experience and self-management for multiple co-occurring symptoms in patients with gastric cancer:a qualitative study[J].Eur J Oncol Nurs，2020(49):101860.
[37] 陈玉梅，张华，闫树英，等.胃癌患者症状困扰及心理弹性与生活质量的相关性[J].中国老年学杂志，2018，38（21）：5337-5339.
[38] 汪丹丹，郑蔚，侯守超，等.胃癌患者化疗期间症状群与生活质量相关性的纵向研究[J].中国全科医学，2019，22（03）：284-291.
[39] M.D.Brundage,J.R.Davidson,W.J.Mackillop.Trading treatment toxicity for survival in locally advanced non-small cell lung cancer[J].J Clin Oncol,1997,15(01):330-340.
[40] 姚芳，石春雷，刘成成，等.中国1996—2015年胃癌经济负担研究的系统评价[J].中华预防医学杂志，2017，51（08）：756-762.
[41] 赫捷，陈万青，李兆申，等.中国胃癌筛查与早诊早治指南（2022，北京）[J].中国肿瘤，2022，31（07）：488-527.

相似文献/References:

[1]孙辉,陈英耀,魏 艳,等.离散选择实验在肿瘤人群治疗偏好中的应用[J].卫生经济研究,2018,(09):3.
　SUN Hui,CHEN Ying-yao,WEI Yan,et al.Application of Discrete selection Experiment in Treatment Preferences of Tumor Population[J].Journal Press of Health Economics Research,2018,(04):3.
[2]孙 辉,陈英耀,任绍聪,等.非小细胞肺癌患者疾病治疗偏好与意愿支付研究[J].卫生经济研究,2018,(09):6.
　SUN Hui,CHEN Ying-yao,REN Shao-cong,et al.Study on Disease Treatment Preference and Willingness Payment in Patients with Non-small Cell Lung Cancer[J].Journal Press of Health Economics Research,2018,(04):6.
[3]孙 辉,陈英耀,何露洋,等.医生治疗非小细胞肺癌的选择偏好研究[J].卫生经济研究,2018,(09):10.
　SUN Hui,CHEN Ying-yao,HE Lu-yang,et al.Doctor's Choice Preference for Non-small Cell Lung Cancer Treatment[J].Journal Press of Health Economics Research,2018,(04):10.
[4]王 京,许 航,马晓静,等.公立医院人事编制改革下医生工作偏好研究——基于离散选择实验的实证分析[J].卫生经济研究,2021,38(4):63.
　WANG Jing,XU Hang,MA Xiao-jing,et al.Study on Doctors' Work Preference Under the Personnel Establishment Reform in Public Hospitals——Empirical Analysis Based on Discrete Choice Experiment[J].Journal Press of Health Economics Research,2021,38(04):63.
[5]吴 爽,邓茜月,曹志辉,等.居民对家庭医生签约服务的需求偏好研究——基于离散选择实验[J].卫生经济研究,2021,38(5):18.
　WU Shuang,DENG Xi-yue,CAO Zhi-hui,et al.Research on Residents' Demand Preference for Contracted Family Doctor Services ——Based on Discrete Selection Experiments[J].Journal Press of Health Economics Research,2021,38(04):18.
[6]燕惊鸿,熊巨洋.湖北省乙型肝炎患者健康管理偏好研究——基于离散选择实验[J].卫生经济研究,2022,39(1):59.
　YAN Jing-hong,XIONG Ju-yang.Study on Health Management Preference of Patients with Hepatitis B in Hubei Province——Based on Discrete Choice Experiment[J].Journal Press of Health Economics Research,2022,39(04):59.
[7]崔梦雨,陈祥华,房琳琳,等.公立医院不同工作年限护理人员岗位选择偏好研究——基于离散选择实验[J].卫生经济研究,2023,40(2):81.
　CUI Mengyu,CHEN Xianghua,FANG Linlin,et al.Study on the Job Selection Preference of Nursing Staff with Different Working Years in Public Hospitals ——Based on Discrete Choice Experiment[J].Journal Press of Health Economics Research,2023,40(04):81.
[8]马慧敏,熊巨洋,唐尚锋,等.终末期肾病患者血液透析服务选择偏好研究 ——基于离散选择实验[J].卫生经济研究,2023,40(9):49.
　MA Huimin,XIONG Juyang,TANG Shangfeng,et al.Study on the Choice Preference of Hemodialysis Service in Patients with End-stage Renal Disease ——Based on Discrete Choice Experiment[J].Journal Press of Health Economics Research,2023,40(04):49.

更新日期/Last Update: 2025-04-02